Tools
Stock profile

Viatris Inc (VTRS)

VTRS · Latest close $20.28 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$20.28
As of Nov 18, 2026
Tracked funds holding
5 of 149
2026 Q2 13F filings
Opened / added
0 / 3
vs previous quarter
Trimmed / exited
1
vs previous quarter

Viatris Inc (VTRS) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 3 funds adding and 1 fund trimming or exiting versus the previous quarter. Latest close $20.28 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Davis Advisors · Rubric Capital Management · Deerfield Management — 5 tracked funds hold VTRS. See all holders.

Insider and Congress activity

No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.

Often held alongside

Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Davis Advisors5.13%75,232,254TRIMMED (-3.8%) Q3 filed Nov 10
Rubric Capital Management4.98%34,168,743ADDED (+2.0%) Q3 filed Nov 16
Deerfield Management3.35%20,206,170HELD Q3 filed Nov 16
Miller Value Partners2.75%733,164ADDED (+0.2%) Q3 filed Nov 16
Greenlight Capital1.13%2,773,470ADDED (+52.6%) Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +26.4% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

21.066.712024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding1,026 of 8,857 filers
Long-only filers among them1,019
Change vs 2026 Q1+22 net · 903 entered · 881 exited
Shares reported, all filers1,042,250,664
Reported value, all filers$15.2B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$14.3B
Net income · FY2025$-3.5B
Total assets · FY2025$37.2B
Shares outstanding1,148,590,864
Market cap (at latest close)$23.3B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 3, 2026.

Short interest

Shares short · Oct 15, 202637,926,100
Share of shares outstanding3.30%
Days to cover4.57

Shares short at recent settlements — Jul 31, 2026: 45.7M · Aug 14, 2026: 37.0M · Aug 31, 2026: 38.6M · Sep 15, 2026: 40.8M · Sep 30, 2026: 42.0M · Oct 15, 2026: 37.9M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 3, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 1K · Sep 15, 2026: 0 · Sep 30, 2026: 670 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 3, 2026.

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Jun 25, 2026Paul CampbellOfficer50,076$809.7KJun 25, 2026SEC filing
Mar 23, 2026Paul CampbellOfficer21,350$283.5KMar 23, 2026SEC filing
Sep 11, 2025Le Goff CorinneOfficer7,032$72.0KSep 11, 2025SEC filing
Nov 12, 2024Campbell PaulOfficer26,925$346.7KNov 11, 2024SEC filing
Aug 20, 2024Malik RajivDirector600,000$7.1MAug 20, 2024SEC filing
Jun 13, 2024Malik RajivAffiliate350,000$3.7MJun 13, 2024SEC filing
May 28, 2024Roman BrianOfficer89,419$928.4KMay 28, 2024SEC filing
Mar 11, 2024Mauro AnthonyOfficer250,000$3.1MMar 11, 2024SEC filing
Mar 5, 2024Campbell PaulOfficer24,353$300.3KMar 5, 2024SEC filing
Mar 5, 2024Lyons Dillon JoEllenDirector20,000$247.2KMar 5, 2024SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Sep 8, 2026FMR LLCSC 13G/A126,764,446.4511.0%Aug 31, 2026SEC filing
Aug 12, 2026DAVIS SELECTED ADVISERSSC 13G/A75,232,2546.5%Jun 30, 2026SEC filing
Aug 6, 2026FMR LLCSC 13G96,362,102.658.3%Jun 30, 2026SEC filing
May 5, 2026DAVIS SELECTED ADVISERSSC 13G/A78,211,1916.8%Mar 31, 2026SEC filing
Apr 30, 2026Vanguard Capital ManagementSC 13G84,807,0837.4%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 4, 2026DAVIS SELECTED ADVISERSSC 13G/A78,177,9846.1%Dec 31, 2025SEC filing
Nov 10, 2025DAVIS SELECTED ADVISERSSC 13G/A69,345,6456.7%Sep 30, 2025SEC filing
Oct 17, 2025BlackRock, Inc.SC 13G/A76,382,1586.6%Sep 30, 2025SEC filing
Aug 11, 2025STATE STREET CORPORATIONSC 13G55,292,5354.7%Jun 30, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 285 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (180), Copyright/Patent/Trademark (155), Budget/Appropriations (93).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Dividend Growth — Dividends raised for more than 10 years

· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%

· Shareholder Yield — Cash returned through dividends and buybacks

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· 52-Week High — Recently printed a new 52-week high

· Top Relative Strength — Top 20% of the universe by 6-month return

Red Flags

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

Key figures

· Dividend Growth — Dividend per share: 0.48 · Dividend yield: 2.5% · Straight dividend years: 5 · 10-yr dividend growth: —

· Cash Flow (FCF) — Latest FCF: $1.9B · FCF yield: 8.4% · Positive FCF years: 3

· Shareholder Yield — Shareholder yield: 4.7% · of which dividends: 2.5% · of which buybacks: 2.2%

· Distress Risk (Altman Z″) — Z″-Score: 0.65 · Working capital / assets: 0.07 · Retained earnings / assets: -0.01 · EBIT / assets: -0.07 · Equity / liabilities: 0.65

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2022 Q1, ranked #23 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together10.0%-21.9%-0.5%-21.4%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold VTRS — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 17, 20262.01 Completion of Acquisition or Disposition of Assets · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Nov 5, 20262.02 Results of Operations and Financial Condition · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing
Oct 8, 20261.01 Entry into a Material Definitive Agreement · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on VTRS

One email a week: the week’s new filings and research. Subscribe free

← VTR  ·  VTS →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.